–As reported at AHA, novel vasodilator failed to improve outcomes in heart failure Short-term treatment with the novel vasodilator ularitide did not lead to improved clinical outcomes in the long term. Results of the TRUE-AHF trial, first presented in preliminary form last November at the American Heart Association annual meeting, have now been published in…
Long-Term Benefit in HF Patients Elusive for Novel Vasodilator
November 13, 2016 by Leave a Comment
–Investigational drug ularitide had no effect on mortality or clinical outcomes NEW ORLEANS — Short term vasodilator treatment for acute heart failure in the hospital did not lead to long term clinical benefits in the largest and most rigorous trial in the field yet performed, researchers said. In the TRUE-AHF trial 2,157 patients with acute…
Recent Comments